MUNICHâ€” Anaplastic lymphoma kinase (ALK) inhibitors are as effective in â€œreal worldâ€ clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studiesâ€”even though randomized trials â€œcherry pickâ€ patients to get statistically valid results. This is the conclusion of a retrospective analysis of data reported at the 2018 annual congress of the European Society for Medical Oncology (ESMO). http://126.96.36.199/slidecenter/esmo2018/attendee/confcal/session/calendar?q=jahanzeb
Progression free survival (PFS) was prolonged to a median of 7.4 months in the overall group of patients treated with ALK-targeted agents. â€œWe were delighted to find out that these patients do as well as patients on clinical trials,â€ said author Mohammad Jahanzeb MD, Professor of Clinical Medicine, Hematology-Oncology and Medical Director of the University of Miami Sylvester Comprehensive Cancer Center in Deerfield Florida talking to the Audio Journal of Oncology. â€œMedian progression free survival was in the same ball-park as we see in clinical trials.â€
Jahanzeb said that prospective clinical trials excluded many real world patients who had comorbid conditions and factors such as brain metastasesâ€”which were often encountered among typical real-world patients.Â â€œSo we thought it was really important to go to a database repository and do a â€œdeep-diveâ€ on the subset of patients positive for ALK,â€ he said, noting that half of these patients typically had brain metastases.